Hikma Pharmaceuticals (LON:HIK) Stock Price Passes Above Two Hundred Day Moving Average – Time to Sell?

Hikma Pharmaceuticals PLC (LON:HIK) shares passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of GBX 1,462.57 and traded as high as GBX 1,635. Hikma Pharmaceuticals shares last traded at GBX 1,615, with a volume of 542,086 shares traded.

Wall Street Analyst Weigh In

Several analysts have commented on HIK shares. Berenberg Bank raised their target price on shares of Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Jefferies Financial Group increased their price target on Hikma Pharmaceuticals from GBX 1,870 to GBX 2,025 and gave the company a “buy” rating in a research report on Tuesday, August 25th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a GBX 1,950 price objective on shares of Hikma Pharmaceuticals in a research report on Friday, August 7th. Finally, Citigroup lifted their target price on Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Six equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of GBX 2,085.83.

Hikma Pharmaceuticals Trading Down 0.6%

The stock has a market capitalization of £3.35 billion, a P/E ratio of 8.87, a P/E/G ratio of 2.38 and a beta of 0.66. The company has a current ratio of 1.98, a quick ratio of 1.27 and a debt-to-equity ratio of 77.57. The business has a 50-day moving average price of GBX 1,594.97 and a two-hundred day moving average price of GBX 1,462.88.

Insider Buying and Selling at Hikma Pharmaceuticals

In other news, insider Tobias Hestler purchased 7,500 shares of Hikma Pharmaceuticals stock in a transaction that occurred on Monday, August 10th. The shares were acquired at an average price of GBX 1,648 per share, for a total transaction of £123,600. Company insiders own 22.04% of the company’s stock.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.